Peter Blume-Jensen was appointed as the chief executive officer of Acrivon Therapeutics, Inc.
2 reports, 2 independent
Updated Aug 5
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Peter Blume-Jensen was appointed as the chief executive officer of Acrivon Therapeutics, Inc.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The company is developing precision medicine using its proprietary AP3 platform.1 source
Peter Blume-Jensen takes the CEO role at Acrivon Therapeutics.1 source
Keep exploring
The entities involved
-
Peter Blume-Jensen
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireAcrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumo